{"protocolSection": {"identificationModule": {"nctId": "NCT00911547", "orgStudyIdInfo": {"id": "0476-029"}, "secondaryIdInfos": [{"id": "2009_596"}], "organization": {"fullName": "Organon and Co", "class": "INDUSTRY"}, "briefTitle": "The Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients (0476-029)", "officialTitle": "A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 2-Period, Parallel-Group Study to Assess the Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients"}, "statusModule": {"statusVerifiedDate": "2022-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "1995-03"}, "primaryCompletionDateStruct": {"date": "1996-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "1996-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-05-29", "studyFirstSubmitQcDate": "2009-06-01", "studyFirstPostDateStruct": {"date": "2009-06-02", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-07-24", "resultsFirstSubmitQcDate": "2010-05-17", "resultsFirstPostDateStruct": {"date": "2010-06-09", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2022-02-01", "lastUpdatePostDateStruct": {"date": "2022-02-03", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Organon and Co", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study will investigate the additive effect of montelukast (MK0476) taken along with inhaled beclomethasone versus inhaled beclomethasone alone."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["chronic asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 642, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "EXPERIMENTAL", "description": "Montelukast + Beclomethasone", "interventionNames": ["Drug: montelukast sodium", "Drug: beclomethasone"]}, {"label": "2", "type": "EXPERIMENTAL", "description": "Montelukast + Placebo inhaler", "interventionNames": ["Drug: montelukast sodium", "Drug: Placebo inhaler"]}, {"label": "3", "type": "EXPERIMENTAL", "description": "Placebo tablet + Beclomethasone", "interventionNames": ["Drug: beclomethasone", "Drug: placebo tablet"]}, {"label": "4", "type": "PLACEBO_COMPARATOR", "description": "Placebo tablet + Placebo inhaler", "interventionNames": ["Drug: Placebo inhaler", "Drug: placebo tablet"]}], "interventions": [{"type": "DRUG", "name": "montelukast sodium", "description": "10 mg tablet taken once daily at bedtime for 16 weeks", "armGroupLabels": ["1", "2"], "otherNames": ["MK0476"]}, {"type": "DRUG", "name": "beclomethasone", "description": "200 ug inhaled, taken twice daily for 16 weeks", "armGroupLabels": ["1", "3"]}, {"type": "DRUG", "name": "Placebo inhaler", "description": "placebo inhaler taken twice daily for 16 weeks", "armGroupLabels": ["2", "4"]}, {"type": "DRUG", "name": "placebo tablet", "description": "placebo tablet taken once daily at bedtime for 16 weeks", "armGroupLabels": ["3", "4"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) in Patients With Chronic Asthma", "description": "Mean percent change from baseline in FEV1 in patients with chronic asthma averaged over 16 weeks for the Beclo and MK+ Beclo groups and averaged over last 10 weeks for the Placebo and MK groups", "timeFrame": "Baseline & over 16 weeks for the Beclomethasone (Beclo) and Montelukast (MK) + Beclo groups and over last 10 weeks for the Placebo and MK groups"}, {"measure": "Mean Change From Baseline in Daytime Symptom Score on the Daytime Asthma Symptoms Diary in Patients With Chronic Asthma", "description": "The daily daytime symptom score was determined by averaging the daily scores (the patient scored his/her symptoms \\[from 0 (best) to 6 (worst)\\] on a daily basis.) for the four questions on the Daytime Asthma Symptoms Diary.\n\nThe average daytime symptom score for the visit was determined by averaging the daily symptom scores over all days between two consecutive visits.", "timeFrame": "Baseline & over 16 weeks for the Beclo and MK + Beclo groups and over last 10 weeks for the Placebo and MK groups"}], "secondaryOutcomes": [{"measure": "Mean Percent Change From Baseline in Total Daily Beta-agonist Medication Use", "description": "Beta-agonist medication use from the daytime and overnight asthma symptoms diaries for each 24-hour period was added to determine the daily total number of puffs used. The average daily number of puffs for the visit was determined as the average daily number of puffs over all days between consecutive visits.", "timeFrame": "Baseline & over 16 weeks for the Beclo and MK + Beclo groups and over last 10 weeks for the Placebo and MK groups"}, {"measure": "Mean Change From Baseline in Morning Peak Flow Rate (PEFR) in Patients With Chronic Asthma", "description": "Morning PEFR was measured in triplicate immediately upon arising before taking any medication and the best value recorded on the overnight asthma symptoms diary. The mean morning PEFR for the visit was determined by averaging all valid PEFR measurements for the days between consecutive visits.", "timeFrame": "Baseline & over 16 weeks for the Beclo and MK + Beclo groups and over last 10 weeks for the Placebo and MK groups"}, {"measure": "Mean Change From Baseline in Nocturnal Asthma Score on the Overnight Asthma Symptoms Diary in Nocturnal Asthmatic Patients Only", "description": "Mean change from baseline in Nocturnal asthma score; the patient scored his/her symptoms \\[from 0 (best) to 3 (worst)\\] on a daily basis. Responses to the question, \"Did you wake up with asthma symptoms?\" (no, once, more than once, awake \"all night\"), were assigned numerical values (0, 1, 2, 3, respectively).\n\nThe average score for the visit was determined by averaging the daily scores over all days between consecutive visits.", "timeFrame": "Baseline & over 16 weeks for the Beclo and MK + Beclo groups and over last 10 weeks for the Placebo and MK groups"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Female patients tested negative for pregnancy and agreed to use appropriate contraceptives through out the study\n* Patient was a nonsmoker\n* Patient was in good general health (except for asthma)\n\nExclusion Criteria:\n\n* Patient was hospitalized\n* Patient was female who was less than 8 weeks postpartum or breast feeding\n* Patient planned to move or vacation away during the study\n* Patient had major surgery within 4 weeks the past 4 weeks\n* Patient has donated blood or participated in a clinical trial within the past 4 weeks\n* Patient was a regular user or recent abuser of alcohol or illicit drugs\n* Patient was 40% over or under normal weight for height", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "15 Years", "maximumAge": "85 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "10588598", "type": "RESULT", "citation": "Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, Peszek I, Zhang J, Reiss TF. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med. 1999 Dec;160(6):1862-8. doi: 10.1164/ajrccm.160.6.9803042."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Patients received inhaled beclomethasone (200 \u03bcg twice daily) starting at the Prestudy Visit and continuing through the single-blind run-in period. Patients who experienced worsening asthma requiring more than albuterol therapy (inhaled or nebulized) did not qualify for randomization.", "recruitmentDetails": "Patients were recruited at 22 sites in the United States (US) and 48 sites in 16 other countries in North America, Europe, Africa, Australia, and Southeast Asia.\n\nPublication incorrectly listed 18 participating countries. Results posting is correct with 17 countries.\n\nPrime therapy period: March 1995 to April 1996.", "groups": [{"id": "FG000", "title": "Placebo", "description": "Montelukast (MK) placebo tablet orally once daily at bedtime. Beclomethasone (beclo) inhaler was removed in a blinded, two-step procedure over 4 weeks (wks): beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising (Weeks 1 to 2)) and 4 puffs (50 \u03bcg/puff) at bedtime (Weeks 1 to 4); beclomethasone placebo inhaler 4 puffs upon arising (Weeks 3 to 16) and 4 puffs at bedtime (Weeks 5 to 16). Albuterol inhaler as needed."}, {"id": "FG001", "title": "Montelukast", "description": "MK 10 mg tablet orally once daily at bedtime. Beclomethasone was removed in a blinded, two-step procedure over 4 weeks: beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising (Weeks 1 to 2) and 4 puffs (50 \u03bcg/puff) at bedtime (Weeks 1 to 4); beclomethasone placebo inhaler 4 puffs upon arising (Weeks 3 to 16) and 4 puffs at bedtime (Weeks 5 to 16). Albuterol inhaler as needed."}, {"id": "FG002", "title": "Beclomethasone", "description": "MK placebo tablet orally once daily at bedtime and beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising and 4 puffs (50 \u03bcg/puff) at bedtime for 16 Weeks. Albuterol inhaler as needed."}, {"id": "FG003", "title": "Montelukast+ Beclomethasone", "description": "MK 10 mg tablet orally once daily at bedtime and beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising and 4 puffs (50 \u03bcg/puff) at bedtime for 16 Weeks. Albuterol inhaler as needed."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Efficacy in last 10 wks to minimize confounding effect of beclo in 1st 4 wks \\& allow beclo washout.", "numSubjects": "48"}, {"groupId": "FG001", "comment": "Efficacy in last 10 wks to minimize confounding effect of beclo in 1st 4 wks \\& allow beclo washout.", "numSubjects": "201"}, {"groupId": "FG002", "comment": "Efficacy analyses were over the 16 weeks of treatment.", "numSubjects": "200"}, {"groupId": "FG003", "comment": "Efficacy analyses were over the 16 weeks of treatment.", "numSubjects": "193"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "37"}, {"groupId": "FG001", "numSubjects": "159"}, {"groupId": "FG002", "numSubjects": "178"}, {"groupId": "FG003", "numSubjects": "177"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "42"}, {"groupId": "FG002", "numSubjects": "22"}, {"groupId": "FG003", "numSubjects": "16"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "27"}, {"groupId": "FG002", "numSubjects": "11"}, {"groupId": "FG003", "numSubjects": "6"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "8"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "Montelukast (MK) placebo tablet orally once daily at bedtime. Beclomethasone (beclo) inhaler was removed in a blinded, two-step procedure over 4 weeks (wks): beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising (Weeks 1 to 2)) and 4 puffs (50 \u03bcg/puff) at bedtime (Weeks 1 to 4); beclomethasone placebo inhaler 4 puffs upon arising (Weeks 3 to 16) and 4 puffs at bedtime (Weeks 5 to 16). Albuterol inhaler as needed."}, {"id": "BG001", "title": "Montelukast", "description": "MK 10 mg tablet orally once daily at bedtime. Beclomethasone was removed in a blinded, two-step procedure over 4 weeks: beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising (Weeks 1 to 2) and 4 puffs (50 \u03bcg/puff) at bedtime (Weeks 1 to 4); beclomethasone placebo inhaler 4 puffs upon arising (Weeks 3 to 16) and 4 puffs at bedtime (Weeks 5 to 16). Albuterol inhaler as needed."}, {"id": "BG002", "title": "Beclomethasone", "description": "MK placebo tablet orally once daily at bedtime and beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising and 4 puffs (50 \u03bcg/puff) at bedtime for 16 Weeks. Albuterol inhaler as needed."}, {"id": "BG003", "title": "Montelukast+ Beclomethasone", "description": "MK 10 mg tablet orally once daily at bedtime and beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising and 4 puffs (50 \u03bcg/puff) at bedtime for 16 Weeks. Albuterol inhaler as needed."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "48"}, {"groupId": "BG001", "value": "201"}, {"groupId": "BG002", "value": "200"}, {"groupId": "BG003", "value": "193"}, {"groupId": "BG004", "value": "642"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "40.50", "lowerLimit": "15", "upperLimit": "75"}, {"groupId": "BG001", "value": "38.00", "lowerLimit": "15", "upperLimit": "75"}, {"groupId": "BG002", "value": "39.00", "lowerLimit": "15", "upperLimit": "78"}, {"groupId": "BG003", "value": "40.00", "lowerLimit": "15", "upperLimit": "76"}, {"groupId": "BG004", "value": "39.00", "lowerLimit": "15", "upperLimit": "78"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "29"}, {"groupId": "BG001", "value": "102"}, {"groupId": "BG002", "value": "96"}, {"groupId": "BG003", "value": "85"}, {"groupId": "BG004", "value": "312"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "99"}, {"groupId": "BG002", "value": "104"}, {"groupId": "BG003", "value": "108"}, {"groupId": "BG004", "value": "330"}]}]}]}, {"title": "Race/Ethnicity", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Caucasian", "categories": [{"measurements": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "189"}, {"groupId": "BG002", "value": "184"}, {"groupId": "BG003", "value": "177"}, {"groupId": "BG004", "value": "590"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "5"}, {"groupId": "BG004", "value": "16"}]}]}, {"title": "Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "6"}, {"groupId": "BG004", "value": "14"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "11"}, {"groupId": "BG003", "value": "5"}, {"groupId": "BG004", "value": "22"}]}]}]}, {"title": "Daytime symptom score", "description": "Daytime symptom score: The patient scored his/her symptoms \\[from 0\n\n(best) to 6 (worst)\\] on a daily basis.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Units on a Scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2.36", "spread": "0.68"}, {"groupId": "BG001", "value": "2.14", "spread": "0.83"}, {"groupId": "BG002", "value": "2.17", "spread": "0.82"}, {"groupId": "BG003", "value": "2.17", "spread": "0.84"}, {"groupId": "BG004", "value": "2.18", "spread": "0.82"}]}]}]}, {"title": "Forced expiratory volume in 1 second (FEV1)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Liters", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2.45", "spread": "0.69"}, {"groupId": "BG001", "value": "2.61", "spread": "0.74"}, {"groupId": "BG002", "value": "2.53", "spread": "0.68"}, {"groupId": "BG003", "value": "2.61", "spread": "0.68"}, {"groupId": "BG004", "value": "2.57", "spread": "0.70"}]}]}]}, {"title": "Morning peak flow rate (PEFR)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Liters/minute", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "406.80", "spread": "73.47"}, {"groupId": "BG001", "value": "419.94", "spread": "92.47"}, {"groupId": "BG002", "value": "402.91", "spread": "86.19"}, {"groupId": "BG003", "value": "412.46", "spread": "91.15"}, {"groupId": "BG004", "value": "411.42", "spread": "88.92"}]}]}]}, {"title": "Nocturnal asthma score", "description": "Nocturnal asthma score: The patient scored his/her symptoms \\[from 0 (best)\n\nto 3 (worst)\\] on a daily basis.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Units on a Scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.57", "spread": "0.46"}, {"groupId": "BG001", "value": "0.41", "spread": "0.45"}, {"groupId": "BG002", "value": "0.35", "spread": "0.44"}, {"groupId": "BG003", "value": "0.43", "spread": "0.47"}, {"groupId": "BG004", "value": "0.41", "spread": "0.46"}]}]}]}, {"title": "Total daily Beta-agonist use", "description": "Number of inhalations (Puffs) of beta-agonist medication", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Puffs", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "4.16", "spread": "3.02"}, {"groupId": "BG001", "value": "3.52", "spread": "2.34"}, {"groupId": "BG002", "value": "3.51", "spread": "2.47"}, {"groupId": "BG003", "value": "3.41", "spread": "2.17"}, {"groupId": "BG004", "value": "3.53", "spread": "2.39"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) in Patients With Chronic Asthma", "description": "Mean percent change from baseline in FEV1 in patients with chronic asthma averaged over 16 weeks for the Beclo and MK+ Beclo groups and averaged over last 10 weeks for the Placebo and MK groups", "populationDescription": "Primary efficacy analyses were based on the intention-to-treat principle, i.e., inclusion of all patients with a baseline and at least one postbaseline measurement. No missing values were imputed. Data collected during discontinuation and unscheduled visits were included the analysis. Differences between treatments are evaluated based on LS means", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of Change", "timeFrame": "Baseline & over 16 weeks for the Beclomethasone (Beclo) and Montelukast (MK) + Beclo groups and over last 10 weeks for the Placebo and MK groups", "groups": [{"id": "OG000", "title": "Placebo", "description": "Montelukast (MK) placebo tablet orally once daily at bedtime. Beclomethasone (beclo) inhaler was removed in a blinded, two-step procedure over 4 weeks (wks): beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising (Weeks 1 to 2)) and 4 puffs (50 \u03bcg/puff) at bedtime (Weeks 1 to 4); beclomethasone placebo inhaler 4 puffs upon arising (Weeks 3 to 16) and 4 puffs at bedtime (Weeks 5 to 16). Albuterol inhaler as needed."}, {"id": "OG001", "title": "Montelukast", "description": "MK 10 mg tablet orally once daily at bedtime. Beclomethasone was removed in a blinded, two-step procedure over 4 weeks: beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising (Weeks 1 to 2) and 4 puffs (50 \u03bcg/puff) at bedtime (Weeks 1 to 4); beclomethasone placebo inhaler 4 puffs upon arising (Weeks 3 to 16) and 4 puffs at bedtime (Weeks 5 to 16). Albuterol inhaler as needed."}, {"id": "OG002", "title": "Beclomethasone", "description": "MK placebo tablet orally once daily at bedtime and beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising and 4 puffs (50 \u03bcg/puff) at bedtime for 16 Weeks. Albuterol inhaler as needed."}, {"id": "OG003", "title": "Montelukast+ Beclomethasone", "description": "MK 10 mg tablet orally once daily at bedtime and beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising and 4 puffs (50 \u03bcg/puff) at bedtime for 16 Weeks. Albuterol inhaler as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "44"}, {"groupId": "OG001", "value": "183"}, {"groupId": "OG002", "value": "198"}, {"groupId": "OG003", "value": "191"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-11.96", "lowerLimit": "-16.28", "upperLimit": "-7.64"}, {"groupId": "OG001", "value": "-5.31", "lowerLimit": "-7.32", "upperLimit": "-3.30"}, {"groupId": "OG002", "value": "0.72", "lowerLimit": "-0.89", "upperLimit": "2.33"}, {"groupId": "OG003", "value": "5.08", "lowerLimit": "3.43", "upperLimit": "6.74"}]}]}]}, {"type": "PRIMARY", "title": "Mean Change From Baseline in Daytime Symptom Score on the Daytime Asthma Symptoms Diary in Patients With Chronic Asthma", "description": "The daily daytime symptom score was determined by averaging the daily scores (the patient scored his/her symptoms \\[from 0 (best) to 6 (worst)\\] on a daily basis.) for the four questions on the Daytime Asthma Symptoms Diary.\n\nThe average daytime symptom score for the visit was determined by averaging the daily symptom scores over all days between two consecutive visits.", "populationDescription": "Primary efficacy analyses were based on the intention-to-treat principle, i.e., inclusion of all patients with a baseline and at least one postbaseline measurement. No missing values for this analysis were imputed. Data collected during discontinuation visits and unscheduled visits were included in this analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Units on a Scale", "timeFrame": "Baseline & over 16 weeks for the Beclo and MK + Beclo groups and over last 10 weeks for the Placebo and MK groups", "groups": [{"id": "OG000", "title": "Placebo", "description": "Montelukast (MK) placebo tablet orally once daily at bedtime. Beclomethasone (beclo) inhaler was removed in a blinded, two-step procedure over 4 weeks (wks): beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising (Weeks 1 to 2)) and 4 puffs (50 \u03bcg/puff) at bedtime (Weeks 1 to 4); beclomethasone placebo inhaler 4 puffs upon arising (Weeks 3 to 16) and 4 puffs at bedtime (Weeks 5 to 16). Albuterol inhaler as needed."}, {"id": "OG001", "title": "Montelukast", "description": "MK 10 mg tablet orally once daily at bedtime. Beclomethasone was removed in a blinded, two-step procedure over 4 weeks: beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising (Weeks 1 to 2) and 4 puffs (50 \u03bcg/puff) at bedtime (Weeks 1 to 4); beclomethasone placebo inhaler 4 puffs upon arising (Weeks 3 to 16) and 4 puffs at bedtime (Weeks 5 to 16). Albuterol inhaler as needed."}, {"id": "OG002", "title": "Beclomethasone", "description": "MK placebo tablet orally once daily at bedtime and beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising and 4 puffs (50 \u03bcg/puff) at bedtime for 16 Weeks. Albuterol inhaler as needed."}, {"id": "OG003", "title": "Montelukast+ Beclomethasone", "description": "MK 10 mg tablet orally once daily at bedtime and beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising and 4 puffs (50 \u03bcg/puff) at bedtime for 16 Weeks. Albuterol inhaler as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "44"}, {"groupId": "OG001", "value": "183"}, {"groupId": "OG002", "value": "198"}, {"groupId": "OG003", "value": "191"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.31", "lowerLimit": "0.08", "upperLimit": "0.54"}, {"groupId": "OG001", "value": "0.27", "lowerLimit": "0.17", "upperLimit": "0.38"}, {"groupId": "OG002", "value": "-0.02", "lowerLimit": "-0.10", "upperLimit": "0.06"}, {"groupId": "OG003", "value": "-0.13", "lowerLimit": "-0.22", "upperLimit": "-0.05"}]}]}]}, {"type": "SECONDARY", "title": "Mean Percent Change From Baseline in Total Daily Beta-agonist Medication Use", "description": "Beta-agonist medication use from the daytime and overnight asthma symptoms diaries for each 24-hour period was added to determine the daily total number of puffs used. The average daily number of puffs for the visit was determined as the average daily number of puffs over all days between consecutive visits.", "populationDescription": "Efficacy analyses were based on the intention-to-treat principle, i.e., inclusion of all patients with a baseline and at least one postbaseline measurement. No missing values for this analysis were imputed. Data collected during discontinuation visits and unscheduled visits were included in this analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent Change", "timeFrame": "Baseline & over 16 weeks for the Beclo and MK + Beclo groups and over last 10 weeks for the Placebo and MK groups", "groups": [{"id": "OG000", "title": "Placebo", "description": "Montelukast (MK) placebo tablet orally once daily at bedtime. Beclomethasone (beclo) inhaler was removed in a blinded, two-step procedure over 4 weeks (wks): beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising (Weeks 1 to 2)) and 4 puffs (50 \u03bcg/puff) at bedtime (Weeks 1 to 4); beclomethasone placebo inhaler 4 puffs upon arising (Weeks 3 to 16) and 4 puffs at bedtime (Weeks 5 to 16). Albuterol inhaler as needed."}, {"id": "OG001", "title": "Montelukast", "description": "MK 10 mg tablet orally once daily at bedtime. Beclomethasone was removed in a blinded, two-step procedure over 4 weeks: beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising (Weeks 1 to 2) and 4 puffs (50 \u03bcg/puff) at bedtime (Weeks 1 to 4); beclomethasone placebo inhaler 4 puffs upon arising (Weeks 3 to 16) and 4 puffs at bedtime (Weeks 5 to 16). Albuterol inhaler as needed."}, {"id": "OG002", "title": "Beclomethasone", "description": "MK placebo tablet orally once daily at bedtime and beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising and 4 puffs (50 \u03bcg/puff) at bedtime for 16 Weeks. Albuterol inhaler as needed."}, {"id": "OG003", "title": "Montelukast+ Beclomethasone", "description": "MK 10 mg tablet orally once daily at bedtime and beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising and 4 puffs (50 \u03bcg/puff) at bedtime for 16 Weeks. Albuterol inhaler as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "44"}, {"groupId": "OG001", "value": "180"}, {"groupId": "OG002", "value": "194"}, {"groupId": "OG003", "value": "189"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "59.20", "lowerLimit": "25.77", "upperLimit": "92.63"}, {"groupId": "OG001", "value": "44.48", "lowerLimit": "28.82", "upperLimit": "60.14"}, {"groupId": "OG002", "value": "6.04", "lowerLimit": "-3.78", "upperLimit": "15.86"}, {"groupId": "OG003", "value": "-5.51", "lowerLimit": "-15.54", "upperLimit": "4.52"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Morning Peak Flow Rate (PEFR) in Patients With Chronic Asthma", "description": "Morning PEFR was measured in triplicate immediately upon arising before taking any medication and the best value recorded on the overnight asthma symptoms diary. The mean morning PEFR for the visit was determined by averaging all valid PEFR measurements for the days between consecutive visits.", "populationDescription": "Efficacy analyses were based on the intention-to-treat principle, i.e., inclusion of all patients with a baseline and at least one postbaseline measurement. No missing values for this analysis were imputed. Data collected during discontinuation visits and unscheduled visits were included in this analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Liters/minute", "timeFrame": "Baseline & over 16 weeks for the Beclo and MK + Beclo groups and over last 10 weeks for the Placebo and MK groups", "groups": [{"id": "OG000", "title": "Placebo", "description": "Montelukast (MK) placebo tablet orally once daily at bedtime. Beclomethasone (beclo) inhaler was removed in a blinded, two-step procedure over 4 weeks (wks): beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising (Weeks 1 to 2)) and 4 puffs (50 \u03bcg/puff) at bedtime (Weeks 1 to 4); beclomethasone placebo inhaler 4 puffs upon arising (Weeks 3 to 16) and 4 puffs at bedtime (Weeks 5 to 16). Albuterol inhaler as needed."}, {"id": "OG001", "title": "Montelukast", "description": "MK 10 mg tablet orally once daily at bedtime. Beclomethasone was removed in a blinded, two-step procedure over 4 weeks: beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising (Weeks 1 to 2) and 4 puffs (50 \u03bcg/puff) at bedtime (Weeks 1 to 4); beclomethasone placebo inhaler 4 puffs upon arising (Weeks 3 to 16) and 4 puffs at bedtime (Weeks 5 to 16). Albuterol inhaler as needed."}, {"id": "OG002", "title": "Beclomethasone", "description": "MK placebo tablet orally once daily at bedtime and beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising and 4 puffs (50 \u03bcg/puff) at bedtime for 16 Weeks. Albuterol inhaler as needed."}, {"id": "OG003", "title": "Montelukast+ Beclomethasone", "description": "MK 10 mg tablet orally once daily at bedtime and beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising and 4 puffs (50 \u03bcg/puff) at bedtime for 16 Weeks. Albuterol inhaler as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "44"}, {"groupId": "OG001", "value": "184"}, {"groupId": "OG002", "value": "197"}, {"groupId": "OG003", "value": "191"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-27.10", "lowerLimit": "-38.96", "upperLimit": "-15.25"}, {"groupId": "OG001", "value": "-15.37", "lowerLimit": "-20.87", "upperLimit": "-9.87"}, {"groupId": "OG002", "value": "2.65", "lowerLimit": "-1.31", "upperLimit": "6.60"}, {"groupId": "OG003", "value": "10.41", "lowerLimit": "6.36", "upperLimit": "14.47"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Nocturnal Asthma Score on the Overnight Asthma Symptoms Diary in Nocturnal Asthmatic Patients Only", "description": "Mean change from baseline in Nocturnal asthma score; the patient scored his/her symptoms \\[from 0 (best) to 3 (worst)\\] on a daily basis. Responses to the question, \"Did you wake up with asthma symptoms?\" (no, once, more than once, awake \"all night\"), were assigned numerical values (0, 1, 2, 3, respectively).\n\nThe average score for the visit was determined by averaging the daily scores over all days between consecutive visits.", "populationDescription": "Efficacy analyses were based on the intention-to-treat principle, i.e., inclusion of all patients with a baseline and at least one postbaseline measurement. No missing values for this analysis were imputed. Data collected during discontinuation visits and unscheduled visits were included in this analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Units on a Scale", "timeFrame": "Baseline & over 16 weeks for the Beclo and MK + Beclo groups and over last 10 weeks for the Placebo and MK groups", "groups": [{"id": "OG000", "title": "Placebo", "description": "Montelukast (MK) placebo tablet orally once daily at bedtime. Beclomethasone (beclo) inhaler was removed in a blinded, two-step procedure over 4 weeks (wks): beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising (Weeks 1 to 2)) and 4 puffs (50 \u03bcg/puff) at bedtime (Weeks 1 to 4); beclomethasone placebo inhaler 4 puffs upon arising (Weeks 3 to 16) and 4 puffs at bedtime (Weeks 5 to 16). Albuterol inhaler as needed."}, {"id": "OG001", "title": "Montelukast", "description": "MK 10 mg tablet orally once daily at bedtime. Beclomethasone was removed in a blinded, two-step procedure over 4 weeks: beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising (Weeks 1 to 2) and 4 puffs (50 \u03bcg/puff) at bedtime (Weeks 1 to 4); beclomethasone placebo inhaler 4 puffs upon arising (Weeks 3 to 16) and 4 puffs at bedtime (Weeks 5 to 16). Albuterol inhaler as needed."}, {"id": "OG002", "title": "Beclomethasone", "description": "MK placebo tablet orally once daily at bedtime and beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising and 4 puffs (50 \u03bcg/puff) at bedtime for 16 Weeks. Albuterol inhaler as needed."}, {"id": "OG003", "title": "Montelukast+ Beclomethasone", "description": "MK 10 mg tablet orally once daily at bedtime and beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising and 4 puffs (50 \u03bcg/puff) at bedtime for 16 Weeks. Albuterol inhaler as needed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "84"}, {"groupId": "OG002", "value": "74"}, {"groupId": "OG003", "value": "85"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.17", "lowerLimit": "-0.01", "upperLimit": "0.35"}, {"groupId": "OG001", "value": "0.18", "lowerLimit": "0.09", "upperLimit": "0.28"}, {"groupId": "OG002", "value": "-0.06", "lowerLimit": "-0.14", "upperLimit": "0.02"}, {"groupId": "OG003", "value": "-0.20", "lowerLimit": "-0.28", "upperLimit": "-0.12"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Over 16 weeks of treatment and for 14 days post-treatment", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Montelukast (MK) placebo tablet orally once daily at bedtime. Beclomethasone (beclo) inhaler was removed in a blinded, two-step procedure over 4 weeks (wks): beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising (Weeks 1 to 2)) and 4 puffs (50 \u03bcg/puff) at bedtime (Weeks 1 to 4); beclomethasone placebo inhaler 4 puffs upon arising (Weeks 3 to 16) and 4 puffs at bedtime (Weeks 5 to 16). Albuterol inhaler as needed.", "seriousNumAffected": 1, "seriousNumAtRisk": 48, "otherNumAffected": 36, "otherNumAtRisk": 48}, {"id": "EG001", "title": "Montelukast", "description": "MK 10 mg tablet orally once daily at bedtime. Beclomethasone was removed in a blinded, two-step procedure over 4 weeks: beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising (Weeks 1 to 2) and 4 puffs (50 \u03bcg/puff) at bedtime (Weeks 1 to 4); beclomethasone placebo inhaler 4 puffs upon arising (Weeks 3 to 16) and 4 puffs at bedtime (Weeks 5 to 16). Albuterol inhaler as needed.", "seriousNumAffected": 4, "seriousNumAtRisk": 201, "otherNumAffected": 150, "otherNumAtRisk": 201}, {"id": "EG002", "title": "Beclomethasone", "description": "MK placebo tablet orally once daily at bedtime and beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising and 4 puffs (50 \u03bcg/puff) at bedtime for 16 Weeks. Albuterol inhaler as needed.", "seriousNumAffected": 6, "seriousNumAtRisk": 200, "otherNumAffected": 139, "otherNumAtRisk": 200}, {"id": "EG003", "title": "Montelukast+ Beclomethasone", "description": "MK 10 mg tablet orally once daily at bedtime and beclomethasone inhaler 4 puffs (50 \u03bcg/puff) upon arising and 4 puffs (50 \u03bcg/puff) at bedtime for 16 Weeks. Albuterol inhaler as needed.", "seriousNumAffected": 1, "seriousNumAtRisk": 193, "otherNumAffected": 123, "otherNumAtRisk": 193}], "seriousEvents": [{"term": "Fracture, Ankle", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "Crisp Dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 200}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 193}]}, {"term": "Pain, Back", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "Crisp Dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 200}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 193}]}, {"term": "Neurological Disorder", "organSystem": "Nervous system disorders", "sourceVocabulary": "Crisp Dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 200}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 193}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "Crisp Dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 201}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 200}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 193}]}, {"term": "Surgery, Nasopharyngeal", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "Crisp Dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 200}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 193}]}, {"term": "Tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "Crisp Dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 200}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 193}]}, {"term": "Laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "Crisp Dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 201}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 200}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 193}]}], "otherEvents": [{"term": "Asthenia/Fatigue", "organSystem": "General disorders", "sourceVocabulary": "Crisp Dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 201}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 200}, {"groupId": "EG003", "numAffected": 3, "numAtRisk": 193}]}, {"term": "Pain, Abdominal", "organSystem": "General disorders", "sourceVocabulary": "Crisp Dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 201}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 200}, {"groupId": "EG003", "numAffected": 10, "numAtRisk": 193}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "Crisp Dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 201}, {"groupId": "EG002", "numAffected": 11, "numAtRisk": 200}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 193}]}, {"term": "Pain, Back", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "Crisp Dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 201}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 200}, {"groupId": "EG003", "numAffected": 10, "numAtRisk": 193}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "Crisp Dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 52, "numAtRisk": 201}, {"groupId": "EG002", "numAffected": 42, "numAtRisk": 200}, {"groupId": "EG003", "numAffected": 50, "numAtRisk": 193}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "Crisp Dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 20, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 75, "numAtRisk": 201}, {"groupId": "EG002", "numAffected": 40, "numAtRisk": 200}, {"groupId": "EG003", "numAffected": 23, "numAtRisk": 193}]}, {"term": "Bronchitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "Crisp Dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 201}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 200}, {"groupId": "EG003", "numAffected": 5, "numAtRisk": 193}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "Crisp Dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 201}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 200}, {"groupId": "EG003", "numAffected": 8, "numAtRisk": 193}]}, {"term": "Infection, Respiratory, Upper", "organSystem": "Infections and infestations", "sourceVocabulary": "Crisp Dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 72, "numAtRisk": 201}, {"groupId": "EG002", "numAffected": 79, "numAtRisk": 200}, {"groupId": "EG003", "numAffected": 70, "numAtRisk": 193}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "Crisp Dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 201}, {"groupId": "EG002", "numAffected": 11, "numAtRisk": 200}, {"groupId": "EG003", "numAffected": 11, "numAtRisk": 193}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "Crisp Dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 201}, {"groupId": "EG002", "numAffected": 16, "numAtRisk": 200}, {"groupId": "EG003", "numAffected": 10, "numAtRisk": 193}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "Crisp Dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 201}, {"groupId": "EG002", "numAffected": 9, "numAtRisk": 200}, {"groupId": "EG003", "numAffected": 8, "numAtRisk": 193}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "Crisp Dictionary", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 48}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 201}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 200}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 193}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Efficacy over 16 weeks of treatment for Beclo and MK+Beclo groups, and last 10 weeks for Placebo and MK groups to minimize confounding effect of beclo in 1st 4 weeks of treatment and to allow beclo washout."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000001507", "term": "Beclomethasone"}, {"id": "C000093875", "term": "Montelukast"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000020024", "term": "Leukotriene Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000065694", "term": "Cytochrome P-450 CYP1A2 Inducers"}, {"id": "D000065693", "term": "Cytochrome P-450 Enzyme Inducers"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}], "browseLeaves": [{"id": "M4800", "name": "Beclomethasone", "asFound": "Domains", "relevance": "HIGH"}, {"id": "M274108", "name": "Montelukast", "asFound": "Conduction", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M21876", "name": "Leukotriene Antagonists", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}